Analytical Data
-
Gene name
GENX-3414
- Application
-
Alternative Names
STBD1; GENX-3414; Starch-binding domain-containing protein 1; Genethonin-1; Glycophagy cargo receptor STBD1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95210
-
Expression Region
1-358aa
-
AA Sequence
MGAVWSALLVGGGLAGALFVWLLRGGPGDTGKDGDAEQEKDAPLGGAAIPGGHQSGSSGLSPGPSGQELVTKPEHLQESNGHLISKTKDLGKLQAASWRLQNPSREVCDNSREHVPSGQFPDTEAPATSETSNSRSYSEVSRNESLESPMGEWGFQKGQEISAKAATCFAEKLPSSNLLKNRAKEEMSLSDLNSQDRVDHEEWEMVPRHSSWGDVGVGGSLKAPVLNLNQGMDNGRSTLVEARGQQVHGKMERVAVMPAGSQQVSVRFQVHYVTSTDVQFIAVTGDHECLGRWNTYIPLHYNKDGFWSHSIFLPADTVVEWKFVLVENGGVTRWEECSNRFLETGHEDKVVHAWWGIH
-
Molecular Weight
65.12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GENX-3414 is a recombinant protein that has garnered significant attention in the field of therapeutic development due to its potential applications in treating various diseases, including autoimmune disorders and cancer. It is derived from the genetic manipulation of specific pathways to enhance its efficacy and safety. Research on GENX-3414 began as scientists sought to create targeted therapies that could modulate immune responses more precisely than traditional treatments. By focusing on this approach, researchers aim to overcome the limitations of existing therapies, which often result in harmful side effects or insufficient efficacy. The protein is engineered to interact with specific receptor sites involved in disease mechanisms, allowing for a more personalized treatment option. Early studies have shown promising results in preclinical models, demonstrating the ability of GENX-3414 to modulate the immune system and inhibit tumor growth without the adverse effects commonly associated with standard chemotherapy. As research continues, further clinical trials are anticipated to validate its effectiveness and safety in human subjects. The growing understanding of its molecular mechanisms and biological pathways will pave the way for potential new treatments, contributing to the broader landscape of precision medicine and enhancing the quality of life for patients with challenging conditions. Overall, GENX-3414 represents a significant advancement in the development of innovative therapeutic strategies aimed at addressing complex health issues.
